diabetestalk.net

Could Theresa May Become The First Ever World Leader With Type 1 Diabetes?

Could Theresa May become the first ever world leader with type 1 diabetes?

Could Theresa May become the first ever world leader with type 1 diabetes?

For the past few days the headlines in the UK, and across the world, have been dominated by the fallout from the UK public vote to leave the European Union. After David Cameron announced his resignation last week, the race to become the Conservative Party’s new leader and by extension the new prime minister has intensified.
One name that has surged towards the top of the list is that of Theresa May.
Theresa May’s career in Parliament
Ms May has been Home Secretary since 2010. She is the longest-serving holder of the prestigious office– one of the great offices of state – for more than 60 years.
Living with type 1 diabetes
In 2013 Theresa was diagnosed with type 1 diabetes after doctors originally believed she had type 2 diabetes. During the winter of 2012 May went to her GP who ran a blood test which showed very high blood glucose levels.
Theresa, who has been MP for Maidenhead since 1997, spoke to the Mail on Sunday at the time, saying:
‘[Type 1 diabetes] doesn’t affect how I do the job or what I do. It’s just part of life… so it’s a case of head down and getting on with it.’
Meeting the type 1 diabetes community
Ms May has attended a number of JDRF events, including the 2015 Sugarplum Ball – which raised £620,000 in support of JDRF, and most recently JDRF’s #Type1Catalyst event in the Houses of Parliament.
The Conservative Party will elect a new leader after a leadership election, set for September this year. This new leader will then, almost certainly, become the new prime minister of the UK.
Karen Addington, Chief Executive of JDRF in the UK:
� Continue reading

Rate this article
Total 1 ratings
Biosimilars Coming to Diabetes Treatments: How, What, Where, and When?

Biosimilars Coming to Diabetes Treatments: How, What, Where, and When?

Congress creates abbreviated licensure pathway for biological products similar to or interchangeable with FDA-approved products.
A biosimilar product is a biologic product that is approved based on demonstrating that it is highly similar to an FDA‐approved biologic product, known as a reference product, and has no clinically meaningful differences in terms of safety and effectiveness from the reference product. Only minor differences in clinically inactive components are allowable in biosimilar products.
Congress, through the Biologics Price Competition and Innovation Act (BPCI Act) of 2009, created an abbreviated licensure pathway for biological products that are demonstrated to be biosimilar to or interchangeable with an FDA-approved biological product. This pathway was established as a way to provide more treatment options, increase access to lifesaving medications, and potentially lower health care costs through competition.
FDA requires biosimilar and interchangeable biological products meet the Agency’s rigorous approval standards. That means patients and health care professionals will be able to rely upon the safety and effectiveness of the biosimilar or interchangeable product, just as they would the reference product.
Prescription medications, especially those for chronic diseases like diabetes and cardiovascular disease have become a major economic burden. Due to rising diagnosis of type 1 and type 2 diabetes, it is understandable why more cost efficient biosimilar products are being developed. Diabetes biosimilar biologic products such as GLP-1 receptor agoni Continue reading

Are Lifestyle Changes Better Than Diabetes Medications?

Are Lifestyle Changes Better Than Diabetes Medications?

Often, patients come to us feeling guilty about their food choices and lifestyle habits. Though guilt rarely is a helpful emotion, remorseful clients can be wonderful to work with when they’re ready to make significant lifestyle changes. But what should we do when clients with newly diagnosed type 2 diabetes are so motivated to reverse the course of their disease with diet and exercise that they refuse medications prescribed by their doctors? I know the power of lifestyle changes, and of course, I want to support my patients’ decisions. But I can’t agree with this choice. Here’s why.
While I truly appreciate the desire to avoid medications and their potential side effects, I know that time is of the essence. I understand what insulin resistance and type 2 diabetes do to the body, how the problem is progressive, how insulin resistance likely has occurred for years before the diabetes diagnosis, how it affects multiple systems in the body, harms the heart and blood vessels, and raises the risk for certain types of cancer.
My quick reply to the “What should I do?” question is to use every tool available. Don’t wait. Work toward permanent lifestyle changes now and take your medications now. Though there are possible side effects to taking medications, there also are side effects to not taking medications. People who successfully manage type 2 diabetes from the time of diagnosis are the ones most likely to have good outcomes years down the line.
I advise my clients to combine lifestyle changes and diabetes medications. Only when they’ve made solid lifestyle chang Continue reading

Innovative Products to Address the Unique Needs of Patients With Diabetes

Innovative Products to Address the Unique Needs of Patients With Diabetes

Sponsored by BD.
Patients with diabetes have unique needs—for example, they may take multiple medications, including insulin, and they may be at a higher risk for complications from illnesses, including vaccine-preventable diseases.1 By some estimates, patients with diabetes see a pharmacist 7 times more often than they see a physician; thus, pharmacists have additional opportunities to talk about the use of medications and other appropriate interventions (eg, vaccinations).2,3
Becton Dickinson (BD), a leader in diabetes innovation and care, was the first company to develop and commercialize disposable syringes and short-needle insulin syringes.4 Today, BD continues to address the unique needs of patients with diabetes by developing innovative technologies that improve injection comfort and convenience to help optimize patient outcomes. Over the past several years, BD has demonstrated the efficacy and safety of shorter needles and has introduced technologies that further improve both the comfort and ease of injection.5-8
BD INNOVATIONS TO ADDRESS UNMET NEEDS
Area for Improvement: Accidental Intramuscular Injection
Innovation: BD NanoTM Pen Needles
Use of BD Nano 4 mm pen needles rather than longer pen needles can significantly lower the risk of accidental intramuscular injection. Patients who use BD Nano 4 mm pen needles may be as much as 30 times less likely to accidentally inject medication intramuscularly than patients who use 8 mm needles.9 To optimize injection comfort, BD Nano 4 mm pen needles combine 2 technologies. First, the BD Nano pen needle has a PentaPoint co Continue reading

Drug for type 2 diabetes provides significant benefits to type 1 diabetic patients

Drug for type 2 diabetes provides significant benefits to type 1 diabetic patients

BUFFALO, N.Y. -- A majority of patients with Type 1 diabetes who were treated with dapagliflozin, a Type 2 diabetes medicine, had a significant decline in their blood sugar levels, according to a new study published in The Lancet Diabetes and Endocrinology. The results are being presented today by the University at Buffalo researcher who led the study at the annual meeting of the European Association for the Study of Diabetes in Lisbon.
Called DEPICT-1, which stands for Dapagliflozin in Patients with Inadequately Controlled Type 1 diabetes, the 24-week study was the first global multicenter investigation of dapagliflozin to test its efficacy and safety in Type 1 diabetes. The double-blind, randomized, three-arm, phase 3 multicenter study was conducted at 143 sites in 17 countries, including the U.S. It was funded by AstraZeneca and Bristol-Myers Squibb, the companies that partnered to develop dapagliflozin.
Participants were 833 patients aged 18-75 who had inadequately controlled blood sugars with a mean baseline hemoglobin A1C (HbA1c) -- a measure of sugar in the blood -- level of 8.53. A1C levels for Type 1 diabetics are considered optimal when they are under seven.
Adjunct to insulin
The results demonstrate that when this drug, a sodium glucose cotransporter-2 inhibitor (SGLT-2) was administered as an adjunct therapy in addition to the insulin that patients with Type 1 diabetes need to survive, it significantly improved outcomes.
"Our paper provides the initial signal that dapagliflozin is safe and effective in patients with Type 1 diabetes and is a promising adjunct tre Continue reading

No more pages to load

Popular Articles

  • Are you diabetic or could you be pre diabetic – World Diabetes Day 2017
    Are you diabetic or could you be pre diabetic – World Diabetes Day 2017

    Women are the gatekeepers of household nutrition and lifestyle habits. They have the potential to drive prevention in their household and beyond. – International Diabetes Federation Diabetes is the fastest growing health issue in Australia today. 1.2 million Australians have been diagnosed. 500,000 are estimated to be undiagnosed type 2 diabetics. And every 5 minutes another Australian develops ...

  • Could People With a “New” Type of Diabetes Be Wrongly Diagnosed With Type 2?
    Could People With a “New” Type of Diabetes Be Wrongly Diagnosed With Type 2?

    According to researchers from the United Kingdom, people who have been diagnosed with a new type of diabetes — known as type 3c diabetes — are “frequently labeled” as having type 2. And the patients who are mistakenly being treated for type 2 have a “greater requirement for insulin.” In a study published in the November 2017 issue of the journal Diabetes Care, which is published by the ...

  • Genetically Engineered Insulin may CAUSE Diabetes Type 1 in Type 2 Diabetics
    Genetically Engineered Insulin may CAUSE Diabetes Type 1 in Type 2 Diabetics

    Just when you think GMO crops have caused enough damage as possible, there’s a new study proving their munificence to a deeper level. A new study shows that GE-created synthetic insulin could actually cause Diabetes Type 1 in Type 2 diabetics. Thank you biotech industry for creating a potentially new way to get diabetes. The study, published in the Journal of Clinical Endocrinology & Metabolism ...

  • World's first diabetes app will be able to check glucose levels without drawing a drop of blood and will be able to reveal what a can of coke REALLY does to sugar levels
    World's first diabetes app will be able to check glucose levels without drawing a drop of blood and will be able to reveal what a can of coke REALLY does to sugar levels

    The world's first health app could monitor people's glucose levels without breaking the skin - a development which has been described as the 'holy grail' in diabetes care. The Epic app could also help people find out if they could develop diabetes and need to make lifestyle changes to avoid it becoming a reality. Users will be able to find out how different food types affect their body; for exampl ...

  • World’s First Diabetes Emergency Kit
    World’s First Diabetes Emergency Kit

    Natural disasters are likely to send anyone into a state of chaos and turmoil. But if you have diabetes, they can be especially dangerous, as they have the ability to completely shatter your management plan. So having a plan is a necessity that many people don’t realize until it’s too late. For one mom, an earthquake caused her to have this epiphany. While in the midst of experiencing the quak ...

  • FDA Approves MiniMed 670G System – World’s First Hybrid Closed Loop System
    FDA Approves MiniMed 670G System – World’s First Hybrid Closed Loop System

    the first hybrid closed loop system in the world! This approval is a significant milestone in the history of diabetes management, and a culmination of many years of dedicated work. With this approval, we are one step closer to delivering a fully automated closed loop system. You may be wondering how this system is different from the MiniMed 630G system we recently launched in the U.S. Advanced Sma ...

  • Diabetes has become one of America’s most expensive diseases
    Diabetes has become one of America’s most expensive diseases

    With an estimated 30 million Americans struggling with diabetes, the disease is one of the nation’s most entrenched chronic conditions. It’s also one of the most expensive. Consider these facts: ▪ In California, roughly 55 percent of adults either have diagnosed diabetes or blood-sugar levels that put them at high risk of developing the disease. That includes roughly 1 in every 3 adults ages ...

  • Can a dual-hormone closed loop delivery systems become a “technical cure” of diabetes?
    Can a dual-hormone closed loop delivery systems become a “technical cure” of diabetes?

    The dual hormone (insulin and glucagon) ‘‘artificial pancreas’’: Promises and challenges Achieving tight glycaemic control without severe hypoglycaemia still is a major challenge in insulin-treated diabetes. While curative cell based and immunological therapies could theoretically provide the ideal solution for patients with diabetes, there are still many issues to be solved. Closed-loop t ...

  • A vegan diet could prevent, treat and even reverse type 2 diabetes, say leading experts this Diabetes Week (12-18 June).
    A vegan diet could prevent, treat and even reverse type 2 diabetes, say leading experts this Diabetes Week (12-18 June).

    Diet and lifestyle have long been regarded as the main causes of type 2 diabetes. Now research suggests that vegans reduce their risk of diabetes by 78% compared with people who eat meat on a daily basis. “Type 2 diabetes is almost always preventable, often treatable, and sometimes reversible through diet and lifestyle changes,” wrote Dr Michael Greger, internationally-renowned physician, in h ...

Related Articles